Compare Novartis AG (NVS) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs ABRDN Physical Gold Shares ETF — how do they compare? Novartis AG trades at $143.75 (market cap $268.57B), while ABRDN Physical Gold Shares ETF trades at $39.92 (market cap $7.03B). The key difference: Novartis AG is far larger — about 38.2× ABRDN Physical Gold Shares ETF's market cap, and Novartis AG pays a 3.31% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| NVS | SGOL | |
|---|---|---|
Market Cap | $268.57B | $7.03B |
Volume | 1,532,573 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $168.62 | $51.41 |
52-Week Low | $121.80 | $37.54 |
Typical Hold Time | 82 Days | 57 Days |
Enterprise Value | $309.89B | — |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.75, up 0.33% on the day, near the consensus price target of $146.00. Recent earnings show mixed quarterly beats and a miss in Q1 2026, with revenue growth to $56.67B in 2025 and a net income margin of 24.67%. Technical indicators signal a bearish trend, while analyst sentiment is mixed with 24% buy ratings. The company recently announced a $7.8B licensing deal with China's Abogen for mRNA therapy, but faces scrutiny over clinical setbacks and M&A strategy.
The outlook for NVS hinges on execution of its pipeline and deal integration amid investor caution. Opportunities include expansion into autoimmune treatments and solid profitability, but risks involve trial failures, regulatory probes, and debt levels rising to 30.26% of assets. Wall Street remains neutral with a slight upside to the price target.
SGOL trades at $39.92, up 2.31% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks key financial ratio data, making fundamental assessment difficult. Recent news highlights gold's sensitivity to Treasury yields and Fed policy, with prices under pressure from rising rates but finding some support from softer inflation data.
The outlook remains cautious due to bearish technicals and macroeconomic headwinds from interest rates. Investment opportunity hinges on gold's safe-haven appeal if economic uncertainty rises, but risks include persistent rate hikes and dollar strength dampening gold demand. Without current fundamentals, valuation is unclear.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
